EMA Advice On PRIME: 'If You Don't Meet The Criteria, Don't Apply'
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA officials expect to be "flooded" with applications for the new priority review scheme.
You may also be interested in...
Breakthrough Requests: FDA Adds Quick Screen To Pare Workload
Hope is to quickly reject obviously inadequate designation requests, but few meet criteria for dismissal so far.
Unsure About ‘Breakthrough’-Worthiness? Talk To FDA First
An early, informal conversation between a sponsor and the review division about the supportive data could help reduce the number of ‘breakthrough therapy’ designation requests that are ultimately denied, FDA and sponsors said.
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.